Yield on Cost (YOC): 3.51%
The yield on cost (YOC) is 3.51%.
GSK Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
3.51%
Yield on Cost for GSK
GSK now pays $1.84 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-24) | $40.80 | 4.51% |
| 5 years ago(2021-06-22) | $39.08 | 4.71% |
| 3 years ago(2023-06-23) | $36.38 | 5.06% |
| 1 year ago(2025-06-27) | $38.58 | 4.77% |
| Buying today(at $52.50) | $52.50 | 3.51% |
If you buy today and the dividend keeps growing
Projection: starting from today's 3.51% yield, assuming the dividend keeps compounding at its historical -3.8% rate. Boards set dividends each year, so actual figures will differ.
Today
3.51%
In 3 years
2.57%
In 5 years
2.09%
In 10 years
1.24%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for GSK plc (GSK).
Starting Yield
3.50%
Ending YOC
1.97%
Year 15 Dividend
$1.03
Cum. Dividends Recd.
$20.58
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $1.84 | — | 3.50% | $0.00 |
| Year 1 | $1.77 | +-3.77% | 3.37% | $1.77 |
| Year 2 | $1.70 | +-3.77% | 3.25% | $3.47 |
| Year 3 | $1.64 | +-3.77% | 3.12% | $5.11 |
| Year 4 | $1.58 | +-3.77% | 3.01% | $6.69 |
| Year 5 | $1.52 | +-3.77% | 2.89% | $8.21 |
| Year 6 | $1.46 | +-3.77% | 2.78% | $9.67 |
| Year 7 | $1.41 | +-3.77% | 2.68% | $11.08 |
| Year 8 | $1.35 | +-3.77% | 2.58% | $12.43 |
| Year 9 | $1.30 | +-3.77% | 2.48% | $13.73 |
| Year 10 | $1.25 | +-3.77% | 2.39% | $14.99 |
| Year 11 | $1.21 | +-3.77% | 2.30% | $16.19 |
| Year 12 | $1.16 | +-3.77% | 2.21% | $17.35 |
| Year 13 | $1.12 | +-3.77% | 2.13% | $18.47 |
| Year 14 | $1.07 | +-3.77% | 2.05% | $19.54 |
| Year 15 | $1.03 | +-3.77% | 1.97% | $20.58 |
Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for GSK plc (GSK)?
- The yield on cost (YOC) for GSK stock is 3.51%.
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels